Patent application number | Description | Published |
20080279892 | Recombinant RSV Virus Expression Systems And Vaccines - The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene. | 11-13-2008 |
20090017517 | Preparation of Negative-Stranded RNA Viruses by Electroporation - The present invention encompasses methods of preparing non-segmented negative-stranded RNA viruses from cells utilizing electroporation. | 01-15-2009 |
20090274727 | Recombinant RSV Virus Expression Systems And Vaccines - The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene. | 11-05-2009 |
20100028377 | Recombinant RSV Virus Expression Systems And Vaccines - The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene. | 02-04-2010 |
20110045023 | Recombinant RSV Virus Expression Systems And Vaccines - The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene. | 02-24-2011 |
20120308602 | Recombinant RSV Virus Expression Systems And Vaccines - The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene. | 12-06-2012 |
20130065309 | Preparation of Negative-Stranded RNA Viruses By Electroporation - The present invention encompasses methods of preparing non-segmented negative-stranded RNA viruses from cells utilizing electroporation. | 03-14-2013 |
20140024076 | Expression Of Soluble Viral Fusion Glycoproteins In Mammalian Cells - The technology relates in part to production (i.e., expression) of recombinant viral fusion glycoproteins and nucleic acids that encode such viral fusion glycoproteins. In some embodiments, human respiratory syncytial virus fusion protein (RSV-F) and human parainfluenza virus 3 fusion protein (hPIV3-F) are expressed. | 01-23-2014 |
20140295409 | METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTORS FOR EXPRESSION OF ANTIGENIC SEQUENCES - The present invention provides an isolated mammalian negative strand RNA virus, | 10-02-2014 |
Patent application number | Description | Published |
20090175899 | RECOMBINANT RSV VIRUS EXPRESSION SYSTEMS AND VACCINES - The present invention relates to genetically engineered recombinant RS viruses and viral vectors which contain heterologous genes which for the use as vaccines. In accordance with the present invention, the recombinant RS viral vectors and viruses are engineered to contain heterologous genes, including genes of other viruses, pathogens, cellular genes, tumor antigens, or to encode combinations of genes from different strains of RSV. | 07-09-2009 |
20100143407 | Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences - The present invention provides an isolated mammalian negative strand RNA virus, | 06-10-2010 |
20100297730 | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus - The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human | 11-25-2010 |